Discrepant findings in immune responses to JC virus in patients receiving natalizumab.
作者信息
Tan Chen S, Chen Yiping, Viscidi Raphael P, Kinkel R Philip, Stein Marion C, Koralnik Igor J
出版信息
Lancet Neurol. 2010 Jun;9(6):565-6; author reply 566-7. doi: 10.1016/S1474-4422(10)70124-1.
Abstract
摘要
相似文献
1
Discrepant findings in immune responses to JC virus in patients receiving natalizumab.
Lancet Neurol. 2010 Jun;9(6):565-6; author reply 566-7. doi: 10.1016/S1474-4422(10)70124-1.
2
JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.
Ann Neurol. 2014 Jun;75(6):925-34. doi: 10.1002/ana.24148. Epub 2014 Jun 10.
3
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Lancet Neurol. 2010 Mar;9(3):264-72. doi: 10.1016/S1474-4422(10)70006-5. Epub 2010 Jan 29.
4
Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy.
J Virol. 2013 May;87(10):6055-9. doi: 10.1128/JVI.00131-13. Epub 2013 Mar 20.
5
[Biological treatment of multiple sclerosis].
Ugeskr Laeger. 2008 Jun 9;170(24):2156-9.
6
Natalizumab therapy for highly active pediatric multiple sclerosis.
JAMA Neurol. 2013 Apr;70(4):469-75. doi: 10.1001/jamaneurol.2013.923.
7
Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
J Manag Care Pharm. 2007 Apr;13(3):287-9. doi: 10.18553/jmcp.2007.13.3.287.
8
JCV detection in multiple sclerosis patients treated with natalizumab.
J Neurol. 2010 Jun;257(6):954-8. doi: 10.1007/s00415-009-5444-4. Epub 2010 Jan 7.
9
JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
JAMA Neurol. 2014 May;71(5):596-602. doi: 10.1001/jamaneurol.2014.63.
10
Low JC virus antibody index during natalizumab treatment less safe than assumed?
Mult Scler. 2015 Dec;21(14):1753-4. doi: 10.1177/1352458515611499. Epub 2015 Oct 8.
引用本文的文献
1
A case of a cerebellar form of progressive multifocal leukoencephalopathy in a patient undergoing peritoneal dialysis.
CEN Case Rep. 2025 Feb;14(1):6-10. doi: 10.1007/s13730-024-00896-w. Epub 2024 Jun 2.
2
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Ann Neurol. 2014 Dec;76(6):792-801. doi: 10.1002/ana.24153. Epub 2014 May 8.
3
Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
PLoS Pathog. 2012;8(11):e1003014. doi: 10.1371/journal.ppat.1003014. Epub 2012 Nov 8.
4
Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.
J Neuroimmune Pharmacol. 2012 Sep;7(3):665-72. doi: 10.1007/s11481-012-9366-z. Epub 2012 May 16.
5
Managing MS in a changing treatment landscape.
J Neurol. 2011 May;258(5):728-39. doi: 10.1007/s00415-011-6009-x. Epub 2011 Mar 25.
6
[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].
Nervenarzt. 2011 Apr;82(4):475-80. doi: 10.1007/s00115-010-3091-8.
本文引用的文献
1
PML risk and natalizumab: more questions than answers.
Lancet Neurol. 2010 Mar;9(3):231-3. doi: 10.1016/S1474-4422(10)70025-9. Epub 2010 Jan 29.
2
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Lancet Neurol. 2010 Mar;9(3):264-72. doi: 10.1016/S1474-4422(10)70006-5. Epub 2010 Jan 29.
3
Asymptomatic reactivation of JC virus in patients treated with natalizumab.
N Engl J Med. 2009 Sep 10;361(11):1067-74. doi: 10.1056/NEJMoa0904267.
4
Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals.
J Virol. 2004 Sep;78(18):10206-10. doi: 10.1128/JVI.78.18.10206-10210.2004.
5
A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
Brain. 2004 Sep;127(Pt 9):1970-8. doi: 10.1093/brain/awh215. Epub 2004 Jun 23.
Zotero 插件